Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. Multicenter trial - Wikipedia
Multicenter trial - Wikipedia
From Wikipedia, the free encyclopedia

A multicenter research trial is a clinical trial that involves more than one independent medical institutions in enrolling and following trial participants.[1] In multicenter trials the participant institutions follow a common treatment protocol and follow the same data collection guidelines, and there is a single coordinating center that receives, processes and analyzes study data.[2][3]

Benefits

[edit]

An important benefit of multicenter trials is that they permit the enrollment of a larger number of participants at a faster rate, in comparison to a single-center trial, putting to use the sources of multiple institutions.[2] This is crucial when the anticipated benefit from a treatment will be relatively small, or an expected outcome is likely to be uncommon, making a larger sample size necessary. Therefore, studies on preventive measures and therapies tend to be designed as multicenter trials. In studying novel pharmaceuticals, Phase III trials, which compare the new treatment to an established one, are usually multicenter ones. In contrast, Phase I trials, which test potential toxicity of the treatment, and Phase II trials, which establish some preliminary efficacy of the tested treatment, are usually single-center trials, as they require fewer participants.[4]

The benefits of multicenter trials also include the potential for a more heterogenous sample of participants, from different geographic locations and a wider range of population groups, treated from physicians of different backgrounds, and the ability to compare results among centers, all of which increase the generalizability of the study. In many cases, efficacy will vary significantly between population groups with different genetic, environmental, and ethnic or cultural backgrounds ("demographic" factors); multicenter trials are better at evaluating these factors, by giving the opportunity for more subgroup analyses. Heterogeneity in the sample means that the findings will be more generalizable.[4] On the other hand, a more heterogeneous study population generally requires a larger sample size to detect a given difference.[2]

References

[edit]
  1. ^ Friedman, LM; Furberg, CD; et al. (2015). "Multicenter Trials". Fundamentals of Clinical Trials. Springer, Cham. p. 427. doi:10.1007/978-3-319-18539-2_21. ISBN 9783319185392. Retrieved 12 February 2024.
  2. ^ a b c Meinert, CL; et al. (1986). "Single-center versus multicenter trials". Clinical Trials: Design, Conduct and Analysis (Online ed.). Oxford Academic. pp. 23–29. doi:10.1093/acprof:oso/9780195035681.003.0004. ISBN 9780199864478.
  3. ^ Bryant, J; et al. (2014). "Multicenter Trials: Rationale and Examples". Wiley StatsRef: Statistics Reference Online (Online ed.). Wiley. p. 1. doi:10.1002/9781118445112.stat04947. ISBN 9781118445112. Retrieved 12 February 2024.
  4. ^ a b Bryant 2014, p. 3.

External links

[edit]
  • ClinicalTrials.gov from US National Library of Medicine
  • Role of ICH GCP and Recruitment Strategies Training of Clinical Sites Staff in Successful Patient Recruitment Rates By Marithea Goberville, Ph.D.
  • IBPA Publications 2005
  • v
  • t
  • e
Clinical research and experimental design
Overview
  • Clinical trial
    • Trial protocols
    • Adaptive clinical trial
  • Academic clinical trials
  • Clinical study design
  • Evidence-based medicine
  • Real world evidence
  • Patient and public involvement
Controlled study
(EBM I to II-1)
  • Randomized controlled trial
    • Scientific experiment
    • Blind experiment
    • Open-label trial
  • Adaptive clinical trial
    • Platform trial
Observational study
(EBM II-2 to II-3)
  • Cross-sectional study vs. Longitudinal study, Ecological study
  • Cohort study
    • Retrospective
    • Prospective
  • Case–control study (Nested case–control study)
  • Case series
  • Case study
  • Case report
Measures
Occurrence
Incidence, Cumulative incidence, Prevalence, Point prevalence, Period prevalence
Association
Risk difference, Number needed to treat, Number needed to harm, Risk ratio, Relative risk reduction, Odds ratio, Hazard ratio
Population impact
Attributable fraction among the exposed, Attributable fraction for the population, Preventable fraction among the unexposed, Preventable fraction for the population
Other
Clinical endpoint, Virulence, Infectivity, Mortality rate, Morbidity, Case fatality rate, Specificity and sensitivity, Likelihood-ratios, Pre- and post-test probability
Trial/test types
  • In vitro
  • In vivo
  • Animal testing
  • Animal testing on non-human primates
  • First-in-man study
  • Multicenter trial
  • Seeding trial
  • Vaccine trial
Analysis of clinical trials
  • Risk–benefit ratio
  • Systematic review
  • Replication
  • Meta-analysis
  • Intention-to-treat analysis
Interpretation of results
  • Selection bias
  • Survivorship bias
  • Correlation does not imply causation
  • Null result
  • Sex as a biological variable
  • Category
  • Glossary
  • List of topics
Retrieved from "https://teknopedia.ac.id/w/index.php?title=Multicenter_trial&oldid=1225057579"
Categories:
  • Clinical research
  • Clinical trials

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id